At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based CEO’ operating in the Medical space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Alexander Isakov
Founder & CEO of Lattis Surgical
Follow Alexander Isakov:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Kevin Lee
Chief Executive Officer of Bicycle Therapeutics
Kevin Lee, Ph.D., MBA, is chief executive officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions. Kevin studied pharmaceutical sciences at Nottingham University followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.
Follow Kevin Lee:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Jason Fisherman
President & CEO of C4 Therapeutics
Follow Jason Fisherman:
About AlloMek Therapeutics, C4 Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Shawn Marcell
Co-Founder, President & CEO of Torus Biosystems
Follow Shawn Marcell:
About Torus Biosystems: Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Nagesh K. Mahanthappa
CEO of Scholar Rock
Nagesh Mahanthappa is a biotechnology entrepreneur with over 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Nagesh Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Nagesh Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Follow Nagesh K. Mahanthappa:
About Scholar Rock: Scholar Rock is discovering and developing a new class of biologic therapies.
John Evans
CEO of Beam Therapeutics
Follow John Evans:
About ARCH Venture Partners, Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Steven L. Hoerter
President and CEO of Deciphera Pharmaceuticals
Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.
Follow Steven L. Hoerter:
About Deciphera Pharmaceuticals: Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Trey Foskett
Co-Founder and CEO of Watchmaker Genomics
Trey Foskett is the Co-Founder and CEO of Watchmaker Genomics.
Follow Trey Foskett:
About Watchmaker Genomics: Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
John Lewandowski
CEO of Disease Diagnostic Group
John R. Lewandowski (Founder/CEO) is a PhD student at MIT in the Mechanosynthesis Group underneath Prof. John Hart, focusing on low-cost diagnostics leveraging the physics of microparticles, optics, magnetism, and self assembly. His interest in disease diagnostics goes back all the way to high school, where he was a two-time state champion in Disease Detectives in Science Olympiad. He graduated in 2012 from Case Western Reserve University with bachelor’s degrees in mechanical engineering, entrepreneurship, economics, and business management, continuing on with a Masters of Engineering and Management degree from CWRU. He has experience in medical device design and commercialization with internships at Cleveland Clinic, General Electric, CWRU, as well as a drug-delivery start-up Recon Therapeutics. He’s also been Managing Partner at Lew & Dowski Capital, LLC for the past four years, scaling a boutique investment fund based on an innovative supply and demand model in a niche market with a quickly growing NAV of $500,000. He has been recognized as a National Defense Science and Engineering Graduate Fellow, a NSF Graduate Research Fellow, a Hertz Foundation Fellowship Finalist, a Tata Fellow, a Don Richards Fellow, a Tau Beta Pi Fellow, a member of Phi Beta Kappa Society, a Forbes 30 under 30 nominee, distinguished in Think Magazine’s 30 under Thirty and Foreign Policy’s 100 Leading Thinkers, and a Lemelson-MIT Prize Inventor. He’s been an author on a dozen papers and holds one patent on drug reconstitution.
Follow John Lewandowski:
About Disease Diagnostic Group, Lew & Dowski Capital: DDG is a pre-revenue medical device company specializing in the development of rapid, accurate, and inexpensive disease diagnostic tests.
Abhishek Jain
CEO of Beacon Dental Partners
Abhishek Jain is the CEO & co-founder of Beacon Dental Partners, located in Massachusetts. At Beacon Dental Partners, Abhishek he is responsible for the oversight and management of all operations and day-to-day functions of all dental clinics. Prior to Beacon Dental Partners, Abhishek was the Founder of TiE Angels Boston, a diversified angel group that invest in start-ups in to Series A rounds. Abhishek has participated in multiple transaction with it’s personal capital. Investments (typically between between $200K-$1M) include Vizibility Inc, (Sold to All State Legal), AdverCar (still operating and growing). Today, TiE Angels is one of the largest angel groups in Boston. Abhishek has been recognized as the “50 Most Influential Indians in New England” by New England Business Journal. Prior to TiE Angels, Abhishek worked at Beacon Tree Capital, SetMeUp, The Blackstone Group, Bain & Company, and Goldman Sachs. Abhishek received his Bachelor’s degree from University of Southern California, where he graduated with honors and was a recipient of multiple prestigious scholarships and received his MBA from Harvard Business School.
Follow Abhishek Jain:
About Beacon Dental Partners: Dental service organization
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Caroline Loew
President & Chief Executive Officer of Glympse Bio
Caroline Loew is the President and Chief Executive Officer at Glympse Bio.
Follow Caroline Loew:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Todd Krueger
President & CEO of AOBiome
Todd Krueger is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States. Prior to joining us, Mr. Krueger had over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform. Mr. Krueger also currently serves as a director of General Automation Laboratory Technologies, Inc. (GALT), a microbiome tools company based in the United States.
Follow Todd Krueger:
About AOBiome: AOBiome is a life sciences company that focuses on transforming human health.
Maya R. Said
CEO and Co-Founder of Outcomes4Me
Maya Said is the Founder and CEO of Outcomes4Me.
Follow Maya R. Said:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Michael Schrader
Co-Founder & CEO of Vaxess Technologies
Michael Schrader is the CEO and co-founder of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world. The company was the winner of the 2013 MassTLC Innovative Life Science Technology of the Year, 2012 Harvard Business Plan Competition and The 2012 Harvard President’s Challenge for Social Entrepreneurship. Prior to founding Vaxess, Michael worked at Google, Toyota, and Honda where he has earned fifteen patents. He holds a BSME from Purdue University and an MBA from Harvard Business School.
Follow Michael Schrader:
About Harvard University, MassChallenge, Vaxess Technologies: Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Simon Read
Founder and CEO of Curie Therapeutics
Simon Read is the Founder and CEO Curie Therapeutics.
Follow Simon Read:
About Curie Therapeutics: Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Eric Mayes
CEO of Endomag
Dr Mayes has over 20 years’ experience in developing and leading materials technology companies. Prior to joining Endomag as CEO in 2010, Eric held executive positions in Cambridge Display Technology (CDT) and NanoMagnetics. He was named the Royal Society of Chemistry’s ‘Entrepreneur of the Year 2003’ for his founding role in NanoMagnetics. Eric is an advisor to the University of Texas at Austin’s ‘Texas Health Catalyst’ and the European Healthtech Translation Advisory Board (HealthtechTAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
Follow Eric Mayes:
About Endomag: Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
George Foot
Co-Founder & Co-CEO of Sixfold Bioscience
George Foot is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow George Foot:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Benedetto Jacopo Buratti
CEO of Bloomia
Follow Benedetto Jacopo Buratti:
About Bloomia, Einblick: Bloomia is a new medical device that automatically compose the doses and allows you to follow the medical care of your loved ones.
Romain Marmot
Deputy CEO, Chief Operating Officer – US, Oncology Division Coordinator, Co-founder of Voluntis
Romain is Chief Operations Officer of Voluntis and heads the company’s North American operations in Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.
Follow Romain Marmot:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Pierre Leurent
Founder & CEO of Voluntis
Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.
Follow Pierre Leurent:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Mick McLean
CEO of Atelerix
Mick is a chemist by training, a biologist by inclination and a businessman by experience, and is CEO for Atelerix. He’s led new ventures and start-up companies in drug discovery and development, pharmaceutical manufacturing, research tools and contract research, and is driven by commercialising great science and growing businesses. He’s easily enthralled by fervent winemakers and plans to own his own vineyard one day…
Follow Mick McLean:
About Atelerix, Atelerix: Atelerix provides storage and transportation of human cells at room temperature to companies.
Jason Gardner
CEO, President & Co-Founder of Magenta Therapeutics
Jason is CEO, President and Cofounder of Magenta Therapeutics, a biotechnology company created to transform stem cell transplantation. He joined Atlas Venture as an Entrepreneur-in-Residence to create Magenta, working with Third Rock Ventures. He has held leadership roles in pharma and biotech over 18 years, where he most recently established and ran the GSK R&D Satellite in Boston. He also created and led the Regenerative Medicine Discovery Performance Unit, a global team across R&D that established the stem cell gene therapy programs in pharma and ran multiple collaborations. Jason joined GSK in 2005 following eight years in the biotech arena to become a member of the lapatinib clinical team that led to the successful new drug application file for Tykerb in breast cancer in 2007. He then joined the CEEDD, later leading Research and Alliance Management, where new alliances were established with multiple biotech companies. In 2009, he created the Stem Cell DPU to deliver on the therapeutic and platform promise in regenerative medicine. Under his stewardship, the stem cell gene therapy alliance was formed with Fondazione Telethon, one of the biggest biomedical charitable foundations in Italy, and GSK’s Rare Disease Unit, and the team spearheaded GSK’s collaboration with the Harvard Stem Cell Institute. Jason was educated at Cambridge University where he received B.A. and M.A. degrees in Natural Sciences. He completed his Ph.D. at Oxford University and was a Research Fellow in Medicine at Harvard University.
Follow Jason Gardner:
About Magenta Therapeutics: Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Vitor Pamplona
CEO of EyeNetra
I am mostly known for starting a smart, connected wave of technologies in eye care. We created the first smartphone add-on to measure the refractive error of the eyes, the first at-home vision test to be self-administered by the patient alone, the first to use virtual reality to improve the experience, the first tele-optometry deployment, the first to allow patients to track their own eyesight over time, and the first to complete an integrated solution to remote refractive care worldwide. All of them are marketed products these days (EyeNetra, EyeQue, OnSight, Blink). My research also established the concept and first prototype of a 3D display that eliminates the need for corrective eyewear altogether (Tailored Displays). I operate in the triple frontier between optics, computer science, and vision science from early research to post-breakeven. We have created and deployed refractive innovations that enable eyecare providers to fulfill a vision correction to the ~4.5B people in need. That vision correction is delivered in various form factors: eyeglasses, contacts, Lasik surgery, self-correcting displays, holograms, virtual and augmented reality add-ons, etc; and through a range of companies and products my technology helped create and deploy over the past years. My executive style is based on transparency, freedom, diversity, and trust. Besides the technical knowledge, I have hands-on experience in corporate governance, marketing, sales, fundraising and finances, business development, and intellectual property, both in an NGO and Startup settings. In the side, I co-founded PUB-Boston and the SciBr Foundation to help catalyze Brazilian innovation worldwide. In the past, I co-founded one of the biggest Java User Groups in Brazil (JavaFree), the first Portuguese-speaking on-line portal for Ruby (RubyOnBr), the first 3D game engine for feature phones (M3GE), deployed 11 other open source projects while working full time as a software developer and architect.
Follow Vitor Pamplona:
About EyeNetra, Path Check, SciBr Foundation: EyeNetra is a developer of an eye diagnostics platform used to measure the correction of users’ vision through smartphone-based technology.
Erik Gatenholm
Co-Founder & CEO of Cellink
Follow Erik Gatenholm:
About BICO, Cellink: Cellink is a biotechnology company optimized bench-top bioprinter for the ultimate bioprinting of human tissues.
Kaigham J. Gabriel
President & CEO of Draper
Ken was most recently the deputy director of the Advanced Technology and Projects (ATAP) group at Google, which he helped establish when he joined the organization in 2012 as Corporate Vice President at Google/Motorola Mobility. From 2009 to 2012, Ken was the Deputy Director, and then Acting Director, of the Defense Advanced Research Projects Agency (DARPA) in the Department of Defense where he led an agency with an annual budget of $3B that is charged with managing the Department’s portfolio of its most cutting-edge projects to both create and avoid technology surprises.
Follow Kaigham J. Gabriel:
About Draper: Draper is a non-profit laboratory focused on applied research, engineering development, education, and technology transfer.
James Gibbons
Co-Founder & CEO of SBR Health
James F. Gibbons is a Co-Founder and Chairman of the Board of Directors at SBR Health since 2010. Jim joined the Stanford faculty in 1957, was appointed Professor of Electrical Engineering in 1964, and dean of the School of Engineering in 1984. In 1983 Jim was named Reid Weaver Dennis Professor of Electrical Engineering and in 1984 the Frederick Emmons Terman Dean of the School of Engineering. Jim served as Dean from September 1984 to June 1996. Jim has been an advisor and board member of public companies Cisco Systems, El Paso Energy, Lockheed Martin, Raychem. Jim’s research accomplishments are in the area of semiconductor device analysis, process physics technology and solar energy. Jim has written or co-written several books and nearly 300 papers. Gibbons was named Special Counsel to Stanford University President and Provost for Industry Relations in 1966. Jim is credited with developing the Tutored Video Instruction Technique, a model for education of engineers, with colleagues from Stanford in 1972. In recent years, Jim applied that model to improve productivity and quality in children’s education, particularly for children of migrant farm workers and at-risk teens. Jim has received many awards and was elected a member of the National Academy of Engineering, the National Academy of Sciences and the American Academy or Arts and Sciences. In 1997, Jim was inducted into the Santa Clara County Business Hall of Fame and was one of three chosen for the Silicon Valley Engineering Hall of Fame. Jim received a B.S. (1953) degree from Northwestern University and a Ph.D. (1956) from Stanford University.
Follow James Gibbons:
About SBR Health, Stanford University: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Christopher Herot
CEO & Co-Founder of SBR Health
Chris Herot is the CEO and co-founder of SBR Health. Prior to launching SBR in 2010, Chris was Chief Product Officer at VSee Lab, a provider of high quality, low bandwidth and low cost videoconferencing solutions to enterprises and governments. Chris has been a successful business and technology leader in several high growth companies, and directed the advanced technology group for several years at Lotus Development (now IBM) where he was responsible for video, mobile and real-time communications solutions. Chris received his BS and MS degrees from the Massachusetts Institute of Technology where he was on the faculty of the group that became the MIT Media Laboratory.
Follow Christopher Herot:
About SBR Health: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Danielle Zurovcik
Founder & CEO of WiCare
Danielle Zurovcik is the founder and CEO of WiCare.
Follow Danielle Zurovcik:
About WiCare: WiCare develops innovative medical devices that are clinically effective and affordable worldwide.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Goutam Reddy
Founder, CEO of Abiogenix
‘Greddy’ devised the overall architecture of the uBox system, including designing the electronics and firmware of the uBox and uKey. Greddy holds past EE design experience from working for MolySym as well as sensing and robotics from the Biomechatronics Group at the MIT Media Lab. He also has relevant developing-world experience from Developing World Prosthetics, a non-profit he co-founded to improve low-cost rehabilitation devices. Greddy received a Master’s in Electrical Engineering and Computer Science (EECS), as well as B.S. degrees in Mathematics and EECS from MIT.
Follow Goutam Reddy:
About Abiogenix: Abiogenix helps patients improve their medication adherence, which in turn reduces healthcare costs for providers and payers and increases
Ben Shaw
CEO of Swift Molecular Diagnostics
Benjamin completed his undergraduate degree in Biological Sciences at the University of Oxford. He was then accepted onto the prestigious Wellcome Trust PhD Studentship for Developmental Biology at the University of Cambridge. He is now strengthening his business knowledge through active engagement with the Accelerate Programme at the Cambridge Judge Business School. This makes him an ideal candidate to communicate the science and the business to potential investors and buyers, in addition to his scientific role within the company.
Follow Ben Shaw:
About Swift Molecular Diagnostics: Swift Molecular Diagnostics is developing a rapid, easy-to-use, cost effective genetic “yes or no” test.
Jung Taek Oh
CEO of UrCare
Jung-Taek Oh is CEO of urCare, a chronic care management service company specialized on bridging non-medical and medical service. We provide better Health outcomes, reduce healthcare cost and make every life meaningful.
Follow Jung Taek Oh:
About UrCare: UrCare connects caregiver agencies to healthcare providers.
Joanna Burnett
Co-founder and CEO of GPrX Data
Follow Joanna Burnett:
About GPrX Data: GPrX Data translates NHS practice level prescribing data into easily-reviewed intelligence.
Jim Huntington
CEO of ApcinteX
Jim Huntington joined APCINTEX as CEO in 2018.
Follow Jim Huntington:
About ApcinteX, University of Cambridge: ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia.
Andrew Baker Campbell
CEO of LEX Diagnostics
Andrew Baker-Campbell is the CEO of LEX Diagnostics.
Follow Andrew Baker Campbell:
About LEX Diagnostics: LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care.
Andrew Baker Campbell
CEO of LEX Diagnostics
Andrew Baker-Campbell is the CEO of LEX Diagnostics.
Follow Andrew Baker Campbell:
About LEX Diagnostics: LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care.